Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design

References

• Mascola JR et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus Type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group." Infect. Dis. 173(2), 340–348 (1996).
   Google Scholar
• Mascola JR et al. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Hum. Retroviruses 9(12), 1175–1184 (1993).
   Google Scholar
• Barouch DH, Letvin NL. Viral evolution and challenges in the development of HIV vaccines. Vaccine 20\(Suppl. 4), A66—A68 (2002).
   Google Scholar
• Barouch DH et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 415(6869), 335–339 (2002).
   PubMed Web of Science ®Google Scholar
• Barouch DH et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys." Viral 77(13), 7367–7375 (2003).
   Google Scholar
• Vogel TU et al. Multispecific vaccine- induced mucosal cytotoxic T-lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. Viral 77(24), 13348–13360 (2003).
   Google Scholar
• Mascola JR et al. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.' Viral. 77(19), 10348–10356 (2003).
   Google Scholar
• Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum.j Infect. Dis. 171(6), 1387–1398 (1995).
   Google Scholar
• Hilleman MR Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19(15–16), 1837–1848 (2001).
   Google Scholar
• Keller MA, Stiehm ER Passive immunity in prevention and treatment of infectious diseases. Clin. Microbial Rev. 13(4), 602–614 (2000).
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr. Top. Microbial Immunot 260,87–108 (2001).
   PubMedGoogle Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell 93(5), 681–684 (1998).
   PubMed Web of Science ®Google Scholar
• Corny MK, Zolla-Pazner S, Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus Type 1 gp41.I Viral 74(13), 6186–6192 (2000).
   Google Scholar
• Golding H et al. Dissection of human immunodeficiency virus Type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Viral 76(13), 6780–6790 (2002).
   Google Scholar
• Binley JM et al. Redox-triggered infection by disulfide-shackled human immunodeficiency virus Type 1 pseudovirions." Viral 77(10), 5678–5684 (2003).
   Google Scholar
• Hansen JE et al. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization." Viral. 64(6), 2833–2840 (1990).
   Google Scholar
• Scanlan CN et al. The broadly neutralizing antihuman immunodeficiency virus Type 1 antibody 2G12 recognizes a cluster of alphal- > 2 mannose residues on the outer face of gp120.1 Viral. 76(14), 7306–7321 (2002).
   Google Scholar
• Ugolini S et al Inhibition of virus attachment to CD4+ target cells is a major mechanism of T-cell line-adapted HIV1 neutralization." Exp. Med. 186(8), 1287–1298 (1997).
   Google Scholar
• Liao HX et al. Imrnunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV Type 1 gp120 envelope glycoproteins. I Viral. 78(10), 5270–5278 (2004).
   Google Scholar
• Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB 10(2), 258–266 (1996).
   Google Scholar
• Ahmad R et al Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating antiHIV1 antibodies and prognostic predictors of HIV infection.' Clin. Immunol 21(3), 227–233 (2001).
   Google Scholar
• Gomez-Roman VR et al Phage-displayed mimotopes recognizing a biologically active antiHIV1 gp120 rnurine monoclonal antibody.' Acquir. Immune Defic. Syndr. 31(2), 147–153 (2002).
   Google Scholar
• Spear GT et al Antibodies to the HIV1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204(2), 609–615 (1994).
   Google Scholar
• Sawyer LA et al Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6(3), 341–356 (1990).
   Google Scholar
• Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV Type 1 in the presence of natural-killer effector cells." Viral. 75(15), 6953–6961 (2001).
   Google Scholar
• Ljunggren K et al Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J. Infect. Dis. 161(2), 198–202 (1990).
   Google Scholar
• Dirnmock NJ. Neutralization of animal viruses. Curr. Top. Microbial Immunot 183,1–149 (1993).
   Google Scholar
• Cao Y et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus Type 1 infection. N Engl. J. Med. 332(4), 201–208 (1995).
   Google Scholar
• Ho DD et al. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. j Viral. 61(6), 2024–2028 (1987).
   Google Scholar
• Moog C et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus Type 1-infected individuals." Virol 71(5), 3734–3741 (1997).
   Google Scholar
• Montefiori DC et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus Type 1 in long-term nonprogressors.1 Infect. Dis. 173(1), 60–67 (1996).
   Google Scholar
• Moore JP et al. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.' Viral 68(1), 469–484 (1994).
   Google Scholar
• Pilgrim AK et al. Neutralizing antibody responses to human immunodeficiency virus Type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176(4), 924–932 (1997).
   Google Scholar
• Wrin T et al Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. Acquir. Immune Defic. Syndr. 7(3), 211–219 (1994).
   Google Scholar
• Pilgrim AK et al. Neutralizing antibody responses to human immunodeficiency virus Type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176(4), 924–932 (1997).
   Google Scholar
• Watkins BA et al. Resistance of human immunodeficiency virus Type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites." Viral 70(12), 8431–8437 (1996).
   Google Scholar
• Richman DD et al. Rapid evolution of the neutralizing antibody response to HIV Type 1 infection. Proc. Nad Acrid Sci. USA 100(7), 4144 4149 Epub 2003 Mar 18 (2003).
   Google Scholar
• Wei X et al Antibody neutralization and escape by HIV-1. Nature 422(6929), 307–312 (2003).
   Google Scholar
• Moore JP, Ho DD. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus Type 1 are highly prevalent in sera of infected humans. J. Viral 67(2), 863–875 (1993).
   Google Scholar
• VanCott TC et al. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunot 155(8), 4100–4110 (1995)•.
   Google Scholar
• Johnson WE, Desrosiers RC. Viralpersistance: HIV's strategies of immune system evasion. Ann. Rev. Med 53, 499–518 (2002).
   PubMedGoogle Scholar
• Stamatos NM et al. Neutralizing antibodies from the sera of human immunodeficiency virus Type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. f Viral. 72(12), 9656–9667 (1998).
   Google Scholar
• Steimer KS et al. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254, 105–108 (1991).
   PubMed Web of Science ®Google Scholar
• Barbas CF 3rd et al. Recombinant human Fab fragments neutralize human Type 1 immunodeficiency virus in vitro. Proc. Natl Acad. Sci. USA 89(19), 9339–9343 (1992).
   Google Scholar
• Thali M et al. Characterization of conserved human immunodeficiency virus Type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. f Viral. 67(7), 3978–3988 (1993).
   Google Scholar
• Trkola A et aZ Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus Type 1.1 Viral. 70(2), 1100–1108 (1996).
   Google Scholar
• Fung MS et aZ Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus Type 1 gp120.1 Virol. 66(2), 848–856 (1992).
   Google Scholar
• Corny MK et al. Human antiV2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus Type 1.1 Viral. 68(12), 8312–8320 (1994).
   Google Scholar
• Javaherian K et al. Principal neutralizing domain of the human immunodeficiency virus Type 1 envelope protein. Proc. Natl Acad. Sci. USA 86(17), 6768–6772 (1989).
   Google Scholar
• Putney SD et al. HTLV-III/LAV- neutralizing antibodies to an E coli-produced fragment of the virus envelope. Science 234(4782), 1392–1395 (1986).
   Google Scholar
• Gorny MK et al. Production of site- selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus Type 1 envelope glycoprotein. Proc. Natl Acad. Sci. USA 88(8), 3238–3242 (1991).
   Google Scholar
• Goudsmit J. Imrnunodominant B-cell epitopes of the HIV -1 envelope recognized by infected and immunized hosts. AIDS 2\(Suppl. 1), S41-S45 (1988).
   Google Scholar
• Xu JY et al. Epitope mapping of two imrnunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus Type 1, using ten human monoclonal antibodies.' Viral. 65(9), 4832–4838 (1991).
   Google Scholar
• Binley JM et al. Human antibody responses to HIV Type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retroviruses 12(10), 911–924 (1996).
   Google Scholar
• Karwowska S et aZ Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 8(6), 1099–1106 (1992).
   Google Scholar
• Pinter A et al. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res. Hum. Retroviruses 9(10), 985–996 (1993).
   Google Scholar
• Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV1. Immunot Today 17(5), 239–246 (1996).
   Google Scholar
• Trkola A et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. I Viral. 69(11), 6609–6617 (1995).
   Google Scholar
• Kessler JA 2nd et al. Recombinanthuman monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus Type 1 primary isolates. AIDS Res. Hum. Retroviruses 13(7), 575–582 (1997).
   Google Scholar
• Hioe CE et al. Neutralization of HIV -1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunot 9(9), 1281–1290 (1997).
   Google Scholar
• D'Souza MP et aZ Neutralization of primary HIV1 isolates by anti-envelope monoclonal antibodies. AIDS 9(8), 867–874 (1995).
   Google Scholar
• Ruben P et al. &cognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus Type 1.j ViroZ 68(8), 4821–4828 (1994).
   Google Scholar
• Hioe CE et id AntiCD4-binding domain antibodies complexed with HIV Type 1 glycoprotein 120 inhibit CD4+ T-cell-proliferative responses to glycoprotein 120. AIDS Res. Hum. Retroviruses 16(9), 893–905 (2000).
   Google Scholar
• Hioe CE et aZ Inhibition of human immunodeficiency virus Type 1 gp120 presentation to CD4 T-cells by antibodies specific for the CD4 binding domain of gp120." Virot 75(22), 10950–10957 (2001).
   Google Scholar
• Chien PC Jr et aZ Human immunodeficiency virus Type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J Viral. 78(14), 7645–7652 (2004).
   Google Scholar
• Feng Y et aZ HIV1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor. Science 272(5263), 872–877 (1996).
   Google Scholar
• Alkhatib G et aZ Determinants of HIV1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions. J Biol. Chem. 272(33), 20420–20426 (1997).
   Google Scholar
• Deng H et al. Identification of a major co- receptor for primary isolates of HIV1. Nature 381(6584), 661–666 (1996).
   Google Scholar
• Xiang SH et aZ Characterization of CD4- induced epitopes on the HIV Type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18(16), 1207–1217 (2002).
   Google Scholar
• Moulard M et aZ Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Nad Acad. Sci. USA 99(10), 6913–6918 (2002).
   Google Scholar
• Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus Type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. j Viral. 77(5), 2859–2865 (2003).
   Google Scholar
• Sullivan N et al. CD4-Induced conformational changes in the human immunodeficiency virus Type 1 gp120 glycoprotein: consequences for virus entry and neutralization.' Viral. 72(6), 4694 4703 (1998).
   Google Scholar
• Sodroski J. Retroviruses of Human AIDS and Related Animal Diseases. M Vicari (Ed.), Elsevier, France (2002).
   Google Scholar
• Leonard CK et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the Type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells." Biol. Chem. 265(18), 10373–10382 (1990).
   Google Scholar
• Abrignani S et al. Priming of CD4+ T-cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Proc. Natl Acad. Sci. USA 87(16), 6136–6140 (1990).
   Google Scholar
• Haigwood NE et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6(7), 855–869 (1990).
   Google Scholar
• Wyatt R et aZ The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686), 705–711 (1998).
   Google Scholar
• Sanders RW et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus Type 1 glycoprotein gp120.1 Viral. 76(14), 7293–7305 (2002).
   Google Scholar
• Bures R et aZ Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus Type 1 from South Africa.' ViroZ 76(5), 2233–2244 (2002).
   Google Scholar
• Calarese DA et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300(5628), 2065–2071 (2003).
   PubMed Web of Science ®Google Scholar
• Robinson HE. New hope for an AIDS vaccine. Nature Rev. Immunot 2(4), 239–250 (2002).
   Google Scholar
• Cao J et al. Replication and neutralization of human immunodeficiency virus Type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. f Viral. 71(12), 9808–9812 (1997).
   Google Scholar
• Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus Type 1 isolate highly susceptible to neutralization by sera from other clades. I ViroZ 72(10), 7840–7845 (1998).
   Google Scholar
• Center RJ et al. The human immunodeficiency virus Type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J Viral. 74(10), 4448–4455 (2000). immunodeficiency virus Type 1.j Viral. 75(9), 4258–4267 (2001).
   Google Scholar
• Rizzuto CD et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280(5371), 1949-1953 (1998).
   Google Scholar
• NVyatt R et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus Type 1 gp120 epitopes induced by receptor binding./ Viral. 69(9), 5723–5733 (1995)•.
   Google Scholar
• NVyatt R et aZ Functional and immunologic characterization of human immunodeficiency virus Type 1 envelope glycoproteins containing deletions of the major variable regions.' Viral. 67(8), 4557–4565 (1993).
   Google Scholar
• Derdeyn CA et al. Envelope-constrained neutralization-sensitive HIV1 after heterosexual transmission. Science 303(5666), 2019-2022 (2004).
   Google Scholar
• Srivastava IK et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.' Viral. 77(4), 2310–2320 (2003).
   Google Scholar
• Kwong PD et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686), 648–659 (1998).
   Google Scholar
• Kwong PD et al. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus." Viral. 74(4), 1961–1972 (2000).
   Google Scholar
• Stanfield RL et al. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (Camb.) 12(2), 193–204 (2004).
   Google Scholar
• Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus Type 1 envelope glycoprotein interactions with the CCR5 coreceptor." Viral. 76(17), 8953–8957 (2002).
   Google Scholar
• Suphaphiphat P et al. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus Type 1 subtype C gp120 on CCR5 utilization./ Virol. 77(6), 3832–3837 (2003).
   Google Scholar
• Sharon M et al. Alternative conformations of HIV1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb.) 11(2), 225–236 (2003).
   Google Scholar
• Yonezawa A et at Replacement of the V3 region of gp120 with SDF-1 preserves the.
   Google Scholar
• Goudsmit J et aZ Human immunodeficiency virus Type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl Acad. Sci. USA 85(12), 4478–4482 (1988).
   Google Scholar
• Corny MK et al. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J. Immunot 159(10), 5114–5122 (1997).
   Google Scholar
• Corny MK et al. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. I Immunot 150(2), 635–643 (1993).
   Google Scholar
• Conley AJ et al. Neutralization of primary human immunodeficiency virus Type 1 isolates by the broadly reactive antiV3 monoclonal antibody, 447-52D. J. Viral. 68(11), 6994–7000 (1994).
   Google Scholar
• Krachmarov CP et aZ V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus Type 1. AIDS Res. Hum. Retroviruses 17(18), 1737–1748 (2001).
   Google Scholar
• Poignard P et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus Type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.' Viral. 77(1), 353–365 (2003).
   Google Scholar
• Corny MK et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus Type 1 primary isolates from various clades. j Viral. 76(18), 9035–9045 (2002).
   Google Scholar
• Andris JS et al. Molecular characterization of five human antihuman immunodeficiency virus Type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response. Proc. Natl Acad. Sci. USA 88(17), 7783–7787 (1991).
   Google Scholar
• Choe H et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114(2), 161–170 (2003).
   Google Scholar
• Parker CE et aZ Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus Type 1 for the neutralizing monoclonal antibody 2F5.1 Viral. 75(22), 10906–10911 (2001).
   Google Scholar
• Zwick MB et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing antihuman immunodeficiency virus Type 1 antibody b12.j Virot 75(14), 6692–6699 (2001).
   Google Scholar
• Coeffier E et aZ Antigenicity and imrnunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19(7–8), 684–693 (2000).
   Google Scholar
• Zwick MB et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus Type 1 glycoprotein gp41.I Viral. 75(22), 10892–10905 (2001).
   Google Scholar
• Sattentau QJ, Zolla-Pazner S, Poignard Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206(1), 713–717 (1995).
   Google Scholar
• Zolla-Pazner S et al. Serotyping of primary human immunodeficiency virus Type 1 isolates from diverse geographic locations by flow cytometry. I Viral. 69(6), 3807–3815 (1995).
   Google Scholar
• Nyambi PN et aZ Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus Type 1 virions of group MI Virot 74(15), 7096–7107 (2000).
   Google Scholar
• Cotropia J et al. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J. Acquir. Immune Defic. Syndr. Hum. Retrovirot 12(3), 221–232 (1996).
   Google Scholar
• Ferrantelli F et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies-implications for acquired immunodeficiency syndrome vaccine.' Infect. Dis. 189(1), 71–74 (2004).
   Google Scholar
• Emini EA et at Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355(6362), 728–730 (1992).
   Google Scholar
• Conley AJ et al. The consequence of passive administration of an antihuman immunodeficiency virus Type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate./ Viral. 70(10), 6751–6758 (1996).
   Google Scholar
• Mosier DE et aZ Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335(6187), 256–259 (1988).
   Google Scholar
• Mosier DE et aZ Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251(4995), 791–794 (1991).
   Google Scholar
• Safrit JT et al. hu-PBL-SCID mice can be protected from HIV-1 infection bypassive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 7 (1), 15–21 (1993).
   Google Scholar
• Gauduin MC et al. Pre- and postexposure protection against human immunodeficiency virus Type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 171(5), 1203–1209 (1995).
   Google Scholar
• Parren PW et al. Protection against HIV-1 infection in hu-PBL-SCID mice bypassive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9(6), F1-F6 (1995).
   Google Scholar
• Parren PW et al. Erratum to 'Relevance of the antibody response against human immunodeficiency virus Type 1 envelope to vaccine design'. Immunot Lett. 58(2), 125–132 (1997).
   Google Scholar
• Parren PW et al. Erratum to 'Relevance of the antibody response against human immunodeficiency virus Type 1 envelope to vaccine design'. Immunot Lett. 58(2), 125–132 (1997).
   Google Scholar
• Mosier DE. Distinct rate and patterns of human CD4+ T-cell depletion in hu-PBL-SCID mice infected with different isolates of the human immunodeficiency virus." Immunot 15(6 Suppl.), 130S-133S (1995).
   Google Scholar
• Mascola JR et al Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD bypassive transfer of neutralizing antibodies.' Viral 73(5), 4009–4018 (1999).
   Google Scholar
• Mascola JR et al Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus bypassive infusion of neutralizing antibodies. Nature Med. 6(2), 207–210 (2000).
   Google Scholar
• Nishimura Y et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl Acad. Sci. USA 100(25), 15131–15136 (2003).
   Google Scholar
• Hofmann-Lehmann R et id Postnatal pre-and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge.' Med. Primatol 31(3), 109–119 (2002).
   Google Scholar
• Safrit JT et al. Imrnunoprophylmds to prevent mother-to-child transmission of HIV-1.1 Acquir. Immune DOc. Syndr. 35(2), 169–177 (2004).
   Google Scholar
• Ruprecht RM et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol. 8(4), 350–358 (2001).
   Google Scholar
• Ferrantelli F et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17(3), 301–309 (2003).
   Google Scholar
• Francis DP et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first Phase III efficacy trials. AIDS 17(2), 147–156 (2003).
   PubMedGoogle Scholar
• Fouts TR et al. Interaction of polyclonal and monoclonal antiglycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV Type 1 isolate relationship to neutralization. AIDS Res. Hum. Retroviruses 14,591–597 (1997).
   Google Scholar
• Sattentau Q.J, Moore JP. Human immunodeficiency virus Type 1 neutralization is determined by epitope exposure on the gp120 oligomer.j Exp. Med 182(1), 185–196 (1995)•.
   Google Scholar
• Broder CC et al. Antigenic implications of human immunodeficiency virus Type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl Acad. Sci. USA 91(24), 11699–11703 (1994).
   Google Scholar
• Earl PL et al Native oligomeric human immunodeficiency virus Type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.1 Viral 68(5), 3015–3026 (1994).
   Google Scholar
• Earl PL, Koenig S, Moss B. Biological and immunological properties of human immunodeficiency virus Type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Viral 65(1), 31–41 (1991).
   Google Scholar
• Earl PL et al Imrnunogenicity and protective efficacy of oligomeric human immunodeficiency virus Type 1 gp140.1 Viral 75(2), 645–653 (2001).
   Google Scholar
• Srivastava IK et al Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J. Viral 76(6), 2835–2847 (2002).
   Google Scholar
• Srivastava IK et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus Type 1 isolate. J. Virol 77(20), 11244 11259 (2003).
   Google Scholar
• Binley JM et al. A recombinant human immunodeficiency virus Type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Viral 74(2), 627–643 (2000).
   Google Scholar
• Farzan M et al. Stabilization of human immunodeficiency virus Type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. I Viral 72(9), 7620–7625 (1998).
   Google Scholar
• Sanders RW et al. Variable-loop-deleted variants of the human immunodeficiency virus Type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.' Viral 74(11), 5091–5100 (2000).
   Google Scholar
• Schulke N et al. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus Type 1 gp140 envelope glycoprotein. I Viral 76(15), 7760–7776 (2002).
   Google Scholar
• Sanders RW et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus Type 1.1 Viral 76(17), 8875–8889 (2002).
   Google Scholar
• Yang X et al. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus Type 1 envelope glycoproteins. Viral 74(12), 5716–5725 (2000).
   Google Scholar
• Yang X et al. Highly stable trimers formed by human immunodeficiency virus Type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Viral 76(9), 4634 4642 (2002).
   Google Scholar
• Earl PL, Doms RW, Moss B. Oligomeric structure of the human immunodeficiency virus Type 1 envelope glycoprotein. Proc. Natl Acad. Sci. USA 87(2), 648–652 (1990).
   Google Scholar
• Earl PL, Moss B. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 9(7), 589–594 (1993).
   Google Scholar
• Binley JM et al Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology 270(1), 237–249 (2000).
   Google Scholar
• VanCott TC et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus Type 1 isolates elicited by immunization with oligomeric gp160. I Viral. 71,4319–4330 (1997).
   Google Scholar
• Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. Virot 75(3), 1165–1171 (2001).
   Google Scholar
• Barnett SW et al. The ability of an oligomeric human immunodeficiency virus Type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.' Viral. 75(12), 5526–5540 (2001).
   Google Scholar
• Cherpelis S et al. DNA vaccination with the human immunodeficiency virus Type 1 SF162De1taV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.' Viral. 75(3), 1547–1550 (2001).
   Google Scholar
• Cherpelis S et al. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunot Lett. 79(1–2), 47–55 (2001).
   Google Scholar
• Buckner C et al. Priming B-cell-mediated antiHIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320(1), 167–180 (2004).
   Google Scholar
• Pal R et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A. Virology 194(2), 833–837 (1993).
   Google Scholar
• Gershoni JM et al. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB 7(12), 1185–1187 (1993).
   Google Scholar
• DeVico AL et al. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus Type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. Virology 211(2), 583–588 (1995).
   Google Scholar
• Srivastava I, Kan E, Sharma V, Sun Y, Ulmer JB, Barnett SW Induction of broadly cross-reactive primary isolate neutralizing antibodies by Env-CD4 complexes. 10th Conference on Retroviruses and Opportunistic Infections (2003).
   Google Scholar
• Celada F et al Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.' E. Med. 172,1143-1150 (1990).
   Google Scholar
• Sweet RW, Truneh A, Hendrickson WA. CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. Curr. Opin. Biotechnol. 2(4), 622–633 (1991).
   Google Scholar
• Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 267(5196), 383–386 (1995)•.
   Google Scholar
• Vita C. Engineering novel proteins by transfer of active sites to natural scaffolds. Curr. Opin. Biotechnot 8(4), 429–434 (1997).
   Google Scholar
• Vita C et al. Novel miniproteins engineered by the transfer of active sites to small natural scaffolds. Biopolymers 47(1), 93–100 (1998).
   Google Scholar
• Vita C et al. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Nad Acad. Sci. USA 96(23), 13091–13096 (1999).
   Google Scholar
• Martin L et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nature Biotechnol 21(1), 71–76 (2003).
   Google Scholar
• Fouts T et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl Acad. Sci. USA 99(18), 11842–11847 (2002).
   Google Scholar
• Pantophlet R et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus Type 1 gp120. Virol. 77(1), 642–658 (2003).
   Google Scholar
• Pantophlet R, Wilson IA, Burton DR Hyperglycosylated mutants of human immunodeficiency virus (HIV) Type 1 monomeric gp120 as novel antigens for HIV vaccine design.' Viral. 77(10), 5889-5901(2003).
   Google Scholar
• Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus Type 1 isolate highly susceptible to neutralization by sera from other clades. j Viral 72, 7840–7845 (1998).
   Google Scholar
• Stamatatos L, Lim M, Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV Type 1 isolates [In Process Citation]. AIDS Res. Hum. Retroviruses 16(10), 981–994 (2000).
   Google Scholar
• Lu S, Wang S, Mascola J et a/. Immunogenicity of monovalent and polyvalent DNA prime/protein boost formulations encoding primary HIV-1 Env ntigens as tested in rabbits and non-human primate models. Keystone Symposium on HIV Vaccine Development: Progress and Prospects. Whistler, British Columbia, Canada. Abstract 245 (2004).
   Google Scholar
• Sambor A, Louder M, Welcher B et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing HIV-1 proteins. Keystone Symposium on HIV Vaccine Development: Progress and Prospects. Whistler, British Columbia, Canada. Abstract 306 (2004).
   Google Scholar
• Weaver EA, Lu Z, Li Y et al. Cross-subtype immune responses of HIV-1 group M consensus Env imrnunogens. 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, USA. Abstract 164 (2004).
   Google Scholar
• Li Y, Weaver EA, Decker JM et al. In vitro and in vivo biological characteristics of subtype C consensus and ancesteral envelope immunogens. 11th Conference on Retrovirus and Opportunitic Infections. San Francisco, USA. Abstract 278 (2004).
   Google Scholar
• Gaschen B et al. Diversity considerations in HIV-1 vaccine selection. Science 296(5577), 2354–2360 (2002).
   Google Scholar
• Learn GH, Doria-Rose N, Mahalanabis M et al. Ancesteral HIV-1B Env protein induces broadly neutralizing antibodies in rabbits. 10th Conference on Retroviruses and Opportunitic Infections. Boston, Massachusetts. Abstract 409 (2003).
   Google Scholar
• Richmond JF et al Studies of the neutralizing activity and avidity of antihuman immunodeficiency virus Type 1 Env antibody elicited by DNA priming and protein boosting. J. Viral. 72(11), p9092-100 (1998).
   Google Scholar
• Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur 38,1 (1924).
   Google Scholar
• Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Vaccine Design: The Subunit and Adjuvant Approach. MF Powell, MJ Newman (Eds), Plenum Press, New York 141–228 (1995)•.
   Google Scholar
• O'Hagan DT et al. Synergistic adjuvant activity of imrnunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20(27–28), 3389–3398 (2002).
   Google Scholar
• O'Hagan D, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2(2), 269–283 (2003).
   Google Scholar
• Singh M et al. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharnz. Res. 18(10), 1476–1479 (2001).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto E Regulation of T-cell immunity by dendritic cells. Cell 106(3), 263–266 (2001).
   PubMed Web of Science ®Google Scholar